1. Market Research
  2. > Biotechnology Market Trends
  3. > Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

Report Details
Nanopharma – Discover Revenue Prospects Now, Benefiting Your Authority
Do you want to find sales potentials of nanomedicine? If so, our new analysis gives you revenue forecasts to 2025 at overall world market, application, product and national level. That way you discover financial data, trends, R&D, opportunities and commercial outlooks.

Visiongain’s study gives you revenue predictions from 2015 for nano-enabled drugs. There you explore trends, technologies and expected products, benefiting your reputation for technological and commercial insight. Discover what the future holds, staying ahead.

Our work explains the potential of nanomedicine to change pharma. See how those developments affect patients, healthcare providers and pharmaceutical companies.

Please read on to explore what drives and shapes that industry, also seeing revenue prediction.

Forecasts and other analysis show you where the best sales opportunities exist
Our new report shows revenue forecasting to 2025, recent results, growth rates and market shares. You explore quantitative and qualitative analyses, business news, research and development. You gain 34 tables, 44 charts and three interviews with other experts.

With that study you assess clinical, technological and commercial trends, results and potentials:
- Why will the nanopharma market expand fast – and what future revenues are possible?
- When will that worldwide industry achieve overall sales in hundreds of billion dollars?
- What products give the most promise for developers, producers and sellers?
- Who are the best-placed companies in that healthcare industry from 2015?
- Where are the most lucrative regions for selling those medicines?
- How will nanotechnological advances affect drug developers, marketers and manufacturers?

Many opportunities exist in healthcare for applications of nanotechnology. With our study you discover what segments are most likely to prosper. See potential sales from 2015.

Why struggle to find data, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations. With our research and analysis, see how to save time and benefit your authority on nanomedicine.

That way you explore what the future holds for nanopharma. The following sections outline how our new investigation helps your work.

Predictions for that world market and submarkets – what sales growth is possible?
Along with revenue prediction for the overall world market for nanopharmaceuticals, our investigation shows you forecasts to 2025 for six individual therapeutic submarkets:
- Cancer
- Cardiovascular disorders
- Central nervous system (CNS) conditions
- Infectious diseases
- Inflammation
- Other applications of nanotechnology in pharmacotherapy.

Our report analyses sales potentials of those technological advances, showing how companies gain. That work can also benefit your authority on nanomedical applications, expanding your reputation for commercial and technological knowledge.

The new investigation discusses what stimulates and restrains sales of those treatments. You explore that industry, also seeing what products can achieve the most success.

Forecasting of leading products’ sales – what revenues are possible for nanodrugs?
How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of 13 brands:
- Abraxane
- Alimta
- Eligard
- Copaxone
- Rapamune
- Neulasta
- Cimzia.

Our sales predictions also cover these products:
- AmBisome
- MIRCERA
- Pegasys
- Emend
- Renagel
- Ritalin.

That work shows how high sales can go, revealing drugs and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges,

Table Of Contents

Nanopharmaceutical Industry and Market: Companies, Products, RandD and Revenue Forecasts 2015-2025
Table of Contents
1. Report Overview
1.1 Overview of the Nanomedicine Industry and Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Nanomedicine
2.1 Nanotechnology - Definition
2.2 Nanomedicine - Size Should Not be the Main Definition
2.3 Nanotechnology - Solutions and Improvements in Medicine
2.4 Nanomedicine - Types of Applications
2.4.1 Drug Delivery
2.4.2 Nanodrugs
2.4.2.1 Nanoparticles - Combinations of Three Dimensions
2.4.2.1.1 Liposomes
2.4.2.1.2 Polymers
2.4.2.1.3 Quantum Dots
2.4.2.1.4 Superparamagnetic Iron Oxide (SPIO)
2.4.2.1.5 Carbon Nanotubes
2.4.2.1.6 Carbon Nanoshells
2.4.2.2 Nanoparticle Functionalisation
2.4.2.2.1 Targeting
2.4.2.2.2 Surface Conjugation
2.4.2.2.3 Improved Bioavailability
2.4.2.2.4 Tunability
2.4.2.2.5 Controlled Release
2.4.3 Implants
2.4.4 Diagnostics
2.4.4.1 Diagnostic Tools
2.4.4.2 Medical Instruments
2.4.4.3 Imaging Tools
2.4.4.4 Theranostics

3. Global Nanomedicine Market, 2015-2025
3.1 Revenue Forecasts of Nanomedicine by Therapeutic Area
3.1.1 Forecast of Nanomedicine for Oncology 2015-2025
3.1.2 Forecast of Nanomedicine for Cardiovascular Uses 2015-2025
3.1.3 Forecast of Nanomedicine for Anti-inflammatory Uses 2015-2025
3.1.4 Forecast of Nanomedicine for Neurology 2015-2025
3.1.5 Forecast of Nanomedicine for Anti-Infective 2015-2025
3.1.6 Forecast of Nanomedicine for Other Therapeutic Areas 2015-2025

4. Nanomedicine Products - Commercial Outlooks from 2015
4.1 Nanomedicine Products - Segmentation
4.1.1 Nanomedicine Products in the Market - Revenue Potentials, 2015-2025
4.1.1.1 Abraxane (Celgene)
4.1.1.2 Doxil (Janssen)
4.1.1.3 Myocet (Teva Pharmaceuticals)
4.1.1.4 ONCASPAR (Baxalta)
4.1.1.5 Alimta (Eli Lilly)
4.1.1.6 Eligard (Sanofi)
4.1.1.7 DaunoXome (Galen)
4.1.1.8 Copaxone (Teva)
4.1.1.9 Rapamune (PF Prism)
4.1.1.10 Neulasta (Amgen)
4.1.1.11 Cimzia (UCB)
4.1.1.12 AmBisome (Astellas Pharma)
4.1.1.13 MIRCERA (Roche)
4.1.1.14 Pegasys (Roche)
4.1.1.15 Emend (Merck)
4.1.1.16 Renagel (Genzyme)
4.1.1.17 Ritalin (Novartis)

5. Leading National Markets, 2015-2025
5.1 Nanomedicine - Leading Markets, 2014
5.2 The US Nanomedicine Market, 2015-2025
5.3 The Japanese Nanomedicine Market, 2015-2025
5.4 The EU Nanomedicine Market, 2015-2025
5.5 The Asia-Pacific Nanomedicine Market, 2015-2025
5.6 Rest of the World Nanomedicine Market, 2015-2025

6. Profiles of Pharmaceutical Companies with Nanotechnology Related Applications
6.1 Sanofi
6.2 BIND Therapeutics
6.3 Merck
6.4 Pfizer
6.5 Cerulean Pharma
6.6 Selecta Biosciences
6.7 Nanobiotix
6.8 Magforce
6.9 Celgene
6.10 Celsion Corporation
6.11 Nanocarrier

7. Research and Development
7.1 Nanoparticles and Nano-enabled Drugs in the Pipeline
7.1.1 DermaVir (Genetic Immunity)
7.1.2 CRLX101 (Cerulean Pharma)
7.1.3 CPX-351 (Celator Pharma)
7.1.4 NC-6004 (NanoCarrier Co.)
7.1.5 NK-105 (Nippon Kayaku Co. Ltd.)
7.1.6 NK-012 (Nippon Kayaku Co. Ltd.)
7.1.7 SGT-53 (SynerGene Therapeutics)
7.1.8 BIND-014 (BIND Biosciences)
7.1.9 ThermoDox (Celsion)
7.1.10 ADI-PEG 20 (Polaris)

8. Qualitative Analysis of the Nanomedicine Market, 2015
8.1 Room for Improvement
8.1.1 Safety and Toxicology Often Yet to be Determined
8.1.2 Establishment of Structures and Collaborations
8.1.3 Regulatory - The Need for Clear Guidelines and Harmonization

9. Research Interviews, 2015
9.1 Dr Peter Wick, Empa, the Swiss Federal Laboratories for Materials Science and Technology
9.1.1 Connecting the Key Players in the Nanomedical Sector in Europe
9.1.2 Nanomedicine Industry in Europe - In Need of an Infrastructure
9.1.3 EU-NCL: Bridging the Major Gaps and Challenges
9.2 Dr Peter D. Suzdak, CEO, Rexahn Pharmaceuticals
9.2.1 Precision-Targeted Therapy - Revolutionizes Cancer Treatment
9.2.2 RX-21101 - Included in NCL's Preclinical Characterization Program
9.2.3 Rexahn's NPDCS Technology - Next Generation Approach to Chemotherapy
9.2.4 Rexahn's Polymer-Drug Conjugate - Improves Efficacy and Reduces Side Effects
9.3 Dr Joost Holthuis, CEO, Cristal Therapeutics, Netherlands
9.3.1 Nanomedicine Industry in Europe
9.3.2 CriPec Based Nanomedicines - Overcome the Drawbacks of Conventional Therapies
9.3.3 CriPec Platform - All the Best Features in a Single System
9.3.4 CriPec Docetaxel - Lead Candidate Product
9.3.5 In Development - CriPec Actively Targeted Nanoparticles Platform
9.3.6 Competitive Advantage Can be Achieved Through Partnering of Parties

10. Conclusions of the Research and Analysis
10.1 Nanotechnology Holds Great Promise in Healthcare
10.2 More Research Needed to Establish Safety
10.3 Harmonization in Definition and Guidelines

List of Tables
Table 1.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 2.1 Advantages of Nanotechnology in Medicine
Table 2.2 Challenges and Solutions - NDDS
Table 3.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.2 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.1 Abraxane Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.2 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.3 Eligard Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.4 Copaxone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.5 Rapamune Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.6 Neulasta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.7 Cimzia Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.8 AmBisome Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.9 MIRCERA Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.10 Pegasys Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.11 Emend Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.12 Renagel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.13 Ritalin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.1 Nanomedicine Market Revenues ($bn) for Leading Regions, 2014-2025
Table 5.2 Nanomedicine Market Share(%) by Leading Regions, 2014-2025
Table 5.3 Prominent Nanomedicine Companies in the US, 2014
Table 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.7 Prominent Nanomedicine Companies in the UK, 2014
Table 5.8 Prominent Nanomedicine Companies in Germany, 2014
Table 5.9 Prominent Nanomedicine Companies in France, 2014
Table 5.10 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.11 RoW Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 8.1 Strengths, Weaknesses, Opportunities and Threats in the Nanomedicine Market, 2015

List of Figures
Figure 1.1 Nanomedicine - Segmented by Application
Figure 2.1 Applications of Nanotechnology in Diagnostics
Figure 2.2 Applications of Nanotechnology in Therapeutics
Figure 2.3 Systems Used in Nanotechnology-enabled Drug Delivery
Figure 2.4 Market Shares of NDDS by System, 2014
Figure 2.5 NDDS: Market Drivers and Restraints, 2015-2025
Figure 2.6 Representation of Nanoparticles
Figure 2.7 Combinations of Layers that Form Nanoparticles
Figure 2.8 Nanoparticles: Market Drivers and Restraints 2015-2025
Figure 2.9 Implants: Market Drivers and Restraints, 2015-2025
Figure 2.10 Diagnostics: Market Drivers and Restraints, 2015-2025
Figure 2.11 Theranostics: Market Drivers and Restraints, 2015-2025
Figure 3.1 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), 2015-2025
Figure 3.2 Applications of Nanotechnology in the Cardiovascular Therapeutic Area
Figure 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), 2015-2025
Figure 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), 2015-2025
Figure 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), 2015-2025
Figure 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), 2015-2025
Figure 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), 2015-2025
Figure 4.1 Nanomedicine - Segmented by Application
Figure 4.2 Proportions of Nano Products by Application, 2014
Figure 4.3 Proportions of Nano Products by Therapeutic Area, 2014
Figure 4.4 Abraxane Revenue Forecast ($bn), 2015-2025
Figure 4.5 Alimta Revenue Forecast ($bn), 2015-2025
Figure 4.6 Eligard Revenue Forecast ($bn), 2015-2025
Figure 4.7 Copaxone Revenue Forecast ($bn), 2015-2025
Figure 4.8 Rapamune Revenue Forecast ($bn), 2015-2025
Figure 4.9 Neulasta Revenue Forecast ($bn), 2015-2025
Figure 4.10 Cimzia Revenue Forecast ($bn), 2015-2025
Figure 4.11 AmBisome Revenue Forecast ($bn), 2015-2025
Figure 4.12 MIRCERA Revenue Forecast ($bn), 2015-2025
Figure 4.13 Pegasys Revenue Forecast ($bn), 2015-2025
Figure 4.14 Emend Revenue Forecast ($bn), 2015-2025
Figure 4.15 Renagel Revenue Forecast ($bn), 2015-2025
Figure 4.16 Ritalin Revenue Forecast ($bn), 2015-2025
Figure 5.1 Leading National Nanomedicine Markets by Share of Global Market (%), 2014
Figure 5.2 Leading National Nanomedicine Markets by Share of Global Market (%), 2019
Figure 5.3 Leading National Nanomedicine Markets by Share of Global Market (%), 2025
Figure 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.7 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.8 RoW Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 7.1 Proportion of Products by Therapeutic Area in Clinical Trials, 2014
Figure 7.2 Products in Clinical Trials by Developmental Phase, 2014

Companies Listed
3M
Abbott
Abraxis
Access
Accord Healthcare
Ademtech
Agave Biosystems
Alcon
Allergan
Alrise Biosystems
AMAG Pharmaceuticals
Amgen
ANABior
Antnano
Apotex
AquaNova
Arrowhead Research
Astellas
AstraZeneca
Avidimer
Axialys Innovations
Azaya Therapeutics
Baxalta
Bayer
BBInternational
BIND Biosciences
BIND Therapeutics
Bioalliance
BioCellChallenge
Biomerieux
BIOMET
BioNanomatrix
Calando Pharmaceuticals
Capsulution
CarlinaTechnologies
Celator
Celator Pharma
Celgene
Cell Constraint Cancer
Celsion Corporation
Cerulean Pharma
Cezanne
ChemBiotech
Chemicell
ChipShop
Cisbio
Colcom Nanotech
Committee for Medicinal Products for Human Use (CHMP)
Cytimmune
Cytoo
Cytoplex Biosciences
DCN Corp
Eli Lilly
EMA
Empa
EndoMagnetics
Enzon Pharmaceuticals
Epeius
Etex
Ethypharm
EU-Nano Characterization Lab (EUNCL)
FDA
Flamel Technologies
Fleet Bioprocessing
Fluigent
Fresenius
Galen
Genetic Immunity
Genzyme
Gilead
GSK
Guerbet
iCEUTICA
Immunigon
IMSTAR
Inanovate
Innova Biosciences
InoDiag
Intas
Invitrogen
Janssen
Keystone Nano
Kylin Therapeutics
Lighthouse Biosciences
Liquidia
LTT Bio-Pharma
Magforce
MagnaMedics
Mantis Deposition
MAST Carbon International
medsqual
Merck and Co.
Midatech
Momento
Mylan
NanoBio
Nanobiotix
Nanocarrier
Nanoco Technologies
NanoCor Therapeutics
NanoDel
Nanoforce
NanoMedSyn
Nanomerics
Nanopore
Nanoprobes
Nanosight
Nanospectra Biosciences
NatCo
National Characterization Laboratory (NCL)
National Nanotechnology Initiatives (NNI)
NIH
Nippon Kayaku Co.
Novagali Pharma
Novartis
Novavax
Novosom AG
NSD
Otsuka
Oxonica
OZ Biosciences
PDS Biotechnology
PF Prism
Pfizer
PharmaSol
Phusis
Polaris
PolyMicrospheres
ProNAi
PST
Pylote
Qiagen
QuantuMD
RegenTec
Responsif
Rexahn Pharmaceuticals
Roche
Sandoz
Sanofi
Selecta Biosciences
Siemens
Sigma-Tau
Silence Therapeutics
Silicon Kinetics
SkyePharma
SmithandNephew
Smiths Medical
Spirogen
SRU Biosystems
SynerGene Therapeutics
Synthon
T2 Biosystems
Taiho
Teva Pharmaceuticals
UCB
XstalBio
Zell Kontakt

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Nanomedicine Market Research Report 2016

Global Nanomedicine Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Nanomedicine Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Nanomedicine industry, focusing on the main regions (North ...

Global Cancer Nanomedicine Market Outlook 2022

Global Cancer Nanomedicine Market Outlook 2022

  • $ 2200
  • Industry report
  • November 2016
  • by Kuick Research

Over the past several years, many innovative and revolutionary techniques have been developed in order to treat cancer. These techniques range from basic surgical removal to X-ray irradiation to system ...

Global Healthcare Nanotechnology (Nanomedicine) Market - Growth, Trends, and Forecasts (2016 - 2021)

Global Healthcare Nanotechnology (Nanomedicine) Market - Growth, Trends, and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

The global nanomedicine market is estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, growing at a CAGR of XX% during the forecast period. As a market, nanomedicine ...


Download Unlimited Documents from Trusted Public Sources

Global Nanomedicine Industry - Forecast

  • November 2016
    23 pages
  • Nanomedicine  

    Personal Genomi...  

    Gene Therapy  

  • United States  

    World  

    Japan  

View report >

Enzyme Industry in the US

  • October 2016
    11 pages
  • Enzyme  

  • United States  

View report >

Biotechnology Industry in the US

  • August 2016
    112 pages
  • Protein  

  • United States  

View report >

Related Market Segments :

Nanomedicine

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.